Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Razis, E; Escudero, MJ; Palmieri, C; Mueller, V; Bartsch, R; Rossi, G; Gam-penrieder, SP; Kolberg, HC; Zdenkowski, N; Pavic, M; Connolly, RM; Rosset, L; Arcuri, J; Tesch, H; Vallejos, C; Retamales, J; Musolino, A; Del Mastro, L; Christodoulou, C; Aebi, S; Paluch-Shimon, S; Gupta, S; Ohno, S; Macpher-son, I; Ekholm, M; Zaman, K; Vidal, M; Chakiba, C; Fumagalli, D; Thulin, A; Witzel, I; Kotecki, N; Gil-Gil, M; Linderholm, B. ESMO Open. 2022 Jun;7(3):100483. doi: 10.1016/j.esmoop.2022.100483. Epub 2022 May 13.

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Brana, I; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Me-sia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Hong, RL; Mendoza, RG; Jia, LY; Chirovsky, D; Norquist, J; Jin, F; Burtness, B. Oral Oncol. 2022 May;128:105815. doi: 10.1016/j.oraloncology.2022.105815. Epub 2022 Apr 2.

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy.

Mayr, B; Reich, B; Greil, R; Niebauer, J. Cancer Med. 2022 Dec;11(24):4946-4953. doi: 10.1002/cam4.4833. Epub 2022 May 18.

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E. Clin Cancer Res. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231.

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Leisch, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, B; Petzer, A; Schreder, M; Kiesl, D; Vallet, S; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Drost, M; Greil, R; Pleyer, L. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advan-ced breast cancer: NeoTRIP Michelangelo randomized study.

Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G. Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. E-pub 2022 Feb 17.

Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT).

Gampenrieder, SP; Dezentje, V; Lambertini, M; de Nonneville, A; Marhold, M; Le Du, F; Serrano, CS; Costa, DA; Blondeaux, E; Del Mastro, L; Bertucci, F; Goncal-ves, A; Bartsch, R; Deleuze, A; Salgado, AC; Vitorino, M; Tinchon, C; Pecen, L; Rinnerthaler, G; Greil, R. ANN ONCOL. 2022; 33: S208-S208.

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict re-sistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Gampenrieder, SP; Steiner, M; Hufnagl, C; Hackl, H; Rinnerthaler, G; Westphal, T; Huemer, F; Monzo-Fuentes, C; Morre, P; Hauser-Kronberger, C; Greil, R. ANN ONCOL. 2022; 33: S141-S141.

Updated Results of Tucatinib versus Placebo in Combination with Trastuzu-mab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB).

Greil, R; Lin, UN; Murthy, KR; Abramson, V; Anders, C; Bachelot, T; Bedard, LP; Borges, V; Cameron, D; Carey, L; Chien, JA; Curigliano, G; DiGiovanna, PM; Gel-mon, K; Hortobagyi, G; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Oliveira, M; Paplomata, E; Pegram, M; Slamon, D; Zelnak, A; Ramos, J; Feng, W; Winer, E. Geburtshilfe Frauenheilkd 2022; 82(04): e4-e5. DOI: 10.1055/s-0042-1746156

REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus en-docrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis.

Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R. ANN ONCOL. 2022; 33: S217-S217.